CK-MB mass test in ischemic myocardial injury. Comparison of two tests: Biomerieux Vidas and Sanofi Access immunoassays
✍ Scribed by Sophie Poirey; Anne Polge; Jean-Pierre Bertinchant; Etiennette Bancel; Jean-Christophe Boyer; Pascale Fabbro-Peray; Bernard Magnan de Bornier; Bertrand Ledermann; Michel Bonnier; Jean-Pierre Bali
- Book ID
- 101270838
- Publisher
- John Wiley and Sons
- Year
- 2000
- Tongue
- English
- Weight
- 53 KB
- Volume
- 14
- Category
- Article
- ISSN
- 0887-8013
No coin nor oath required. For personal study only.
✦ Synopsis
The analytical and clinical performances of the new fluorescent immunoassay (CK-MB mass Vidas-BioMerieux) were examined and compared to the chemiluminescent test (CK-MB mass Access-Sanofi-Pasteur). Assay precisions of the CK-MB Vidas test within-assay or between-assay were less than 5.4 and 5.3%, respectively. Linearity was tested up to 214 µg/L. The CK-MB Vidas test was free of interference with CK-BB, CK-MM, and macro-CK. One hundred nineteen blood samples from patients with ischemic myocardial injury (IMI): acute myocardial infarction (AMI), suspected myocar-dial contusion (SMC), and unstable angina pectoris (UA), were tested using both immunoassays. In AMI, a good correlation was found (Y [CK-MB Access] = 1.1372 × [CK-MB Vidas] -6.3902; r 2 = 0.96). In UA and SMC, low values were observed and both methods were well correlated (Y [CK-MB Access] = 1.3662 × [CK-MB Vidas] + 0.0671; r 2 = 0.97). Clinical data were in good agreement with both immunoassays. ROC analysis performed in AMI demonstrated that the clinical performances of the two assays were similar.